UPDATED: Bristol-Myers adds promising survival update on breakthrough cancer program

John Carroll Bristol-Myers Squibb has added a few more brushstrokes to the very promising picture that's emerging from early-stage studies of nivolumab, a top PD-1 checkpoint receptor ...

UPDATED: Aragon begets Seragon as VCs bankroll $30M cancer drug spinoff

John Carroll Now that J&J has wrapped up the $ 1 billion acquisition of Aragon and its next-gen treatment for castration-resistant prostate cancer, the biotech's founders can ...

UPDATED: Fresenius punished distributor for selling its drug for executions

Eric Palmer German drugmaker Fresenius Kabi punished a U.S. wholesaler this year after it mistakenly sold its anesthetic propofol to the state of Missouri, which intended to use it ...

UPDATED: Ariad hammered on toxicity concerns for leukemia drug Iclusig

John Carroll Ariad Pharmaceuticals slammed the brakes on new trial enrollment and rolled out a lower dosing schedule for patients in a slate of ongoing studies of Iclusig (ponatinib) ...

UPDATED: Pfizer nabs autoimmune disease drug rights for $25M upfront

John Carroll Currently, patients with autoimmune diseases get transfusions of human intravenous immunoglobulin to bolster their antibody defense system, essential in repelling diseases. ...

UPDATED: Yale biotech spinout launches with $18M and a new approach to cancer

John Carroll Canaan Partners and 5AM Ventures are launching a new Yale spinout focused on a new approach to shutting down proteins. FierceBiotech News

UPDATED: San Diego biotech insider accused of shooting RNAi expert and brother-in-law

Ryan McBride San Diego police say that biotech entrepreneur Hans Petersen shot and wounded his brother-in-law Ron Fletcher and the University of California, San Diego scientist Steven ...

UPDATED: Merck demand triggers expanding patent war with Gilead over sofosbuvir

John Carroll Gilead is rolling out its big legal guns to defend its control of the experimental hepatitis C drug sofosbuvir, one of the most valuable therapies in the industry's ...

UPDATED: Amgen closing in on $10.5B Onyx buyout

John Carroll Amgen appears close to bagging its biotech prey. After starting out with a $ 120-a-share offer for Onyx, the giant biopharma company appears to have settled on a final ...

UPDATED: Quest grabs $485M in deal to cash out of breakthrough cancer dug ibrutinib

John Carroll Two years ago, Quest Diagnostics picked up Celera and its gene-based testing tech for $ 657 million in cash. And today it cashed in a lottery ticket it picked up in the ...

UPDATED: Reported Form 483 may explain Ranbaxy not getting Diovan to market

Eric Palmer Ranbaxy Laboratories had the 6-month exclusive right to produce a generic of Novartis' blockbuster hypertension fighter Diovan. But the patent loss came and went months ...

UPDATED: Charmed by orphan drugs, suitors line up for ViroPharma

Carly Helfand While the U.S. drug market may be shrinking, specialty drugs are on the up-and-up–and drugmakers are taking note. Orphan drugs for rare diseases are hot commodities, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS